winbull的个人主页 - 老虎社区

winbull

winbull

暂无个人介绍

IP属地：未知

157关注

5粉丝

5主题

0勋章

2021-09-22

$Cassava Sciences Inc(SAVA)$Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。

2021-08-30

$Cassava Sciences Inc(SAVA)$Sava基本筑底横盘，等待消息面来决定向上或向下？

2021-08-30

$Cassava Sciences Inc(SAVA)$截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。

2021-09-18

$Cassava Sciences Inc(SAVA)$9月21日阿尔茨海默症日期待phase 3启动等利好消息！

2021-09-04

$Cassava Sciences Inc(SAVA)$Sava今天没有什么利空消息啊，为什么跌这么狠？

2021-09-10

$Cassava Sciences Inc(SAVA)$如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。

2021-09-02

$Cassava Sciences Inc(SAVA)$Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的

04-18

说说你对这篇新闻的看法...

“减肥神药”进入口服时代，礼来登顶“减肥药王”？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3561484276442419","uuid":"3561484276442419","gmtCreate":1598390404789,"gmtModify":1614224747874,"name":"winbull","pinyin":"winbull","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":157,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":5,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":425760610320536,"gmtCreate":1744955620558,"gmtModify":1744955622512,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425760610320536","repostId":"1170316139","repostType":4,"repost":{"id":"1170316139","kind":"news","pubTimestamp":1744940179,"share":"https://www.laohu8.com/m/news/1170316139?lang=&edition=full","pubTime":"2025-04-18 09:36","market":"us","language":"zh","title":"“减肥神药”进入口服时代，礼来登顶“减肥药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1170316139","media":"华尔街见闻","summary":"数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。登顶减肥药之王？报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。","content":"<html><head></head><body><blockquote><p>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而<a href=\"https://laohu8.com/S/LLY\">礼来</a>已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。</p></blockquote><p style=\"text-align: justify;\">礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。</p><p style=\"text-align: justify;\">市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下自2023年8月以来的最大单日涨幅。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe90ecd263678e278cba37dd80d837f5\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: justify;\">与此同时，长期占据GLP-1市场主导地位的<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>股价则大幅收跌近8%。</p><p style=\"text-align: justify;\">根据礼来公布发布的新闻稿，其口服GLP-1药物orforglipron在3期临床试验中“展示了统计学上显著的疗效结果，且安全性与注射型GLP-1药物一致”。</p><p style=\"text-align: justify;\">数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3719b80ed8bbed049f77705d8b2b4a75\" title=\"\" tg-width=\"873\" tg-height=\"530\"/></p><p style=\"text-align: justify;\">相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。</p><p style=\"text-align: justify;\">&#34;这些数据代表了一款一上市就能成为重磅产品的最佳情况，&#34;Jefferies分析师Akash Tewari表示。</p><p style=\"text-align: justify;\">瑞穗证券医疗保健专家Jared Holz表示，礼来将在相当长一段时间内保持该类别中的卓越地位，因为基于这些数据，其领先于制药和生物技术领域竞争对手的优势正在扩大。</p><p style=\"text-align: justify;\"><strong>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。</strong></p><p style=\"text-align: justify;\">礼来公司董事长兼CEO David Ricks在一份声明中写道：</p><blockquote><p style=\"text-align: justify;\">&#34;作为一种方便的每日一次口服药丸，Orforglipron可能提供了一个新选择，如获批准，可迅速大规模生产和推出，供全球人使用。&#34;</p></blockquote><h2 id=\"id_1383858797\">口服药物：便利性与制造优势的双重胜利</h2><p style=\"text-align: justify;\">Orforglipron是一种更便捷的口服替代GLP-1注射剂的治疗方案，这给礼来带来了超越诺和诺德等竞争对手的潜在优势。</p><p style=\"text-align: justify;\">礼来的Orforglipron不仅在疗效上具有竞争力，其口服给药方式还提供了显著的便利性优势。</p><p style=\"text-align: justify;\">据报道，虽然目前市场上已有GLP-1类药物如Wegovy获得巨大成功，但这些药物必须以每周注射的方式给药，这限制了它们的使用范围。</p><blockquote><p style=\"text-align: justify;\">如果Orforglipron能以简单的口服形式提供类似的效果，它有潜力接触到更多患者并成为重大的市场颠覆者。</p></blockquote><p style=\"text-align: justify;\">除了便利性外，礼来还在积极准备大规模生产Orforglipron。该公司最近披露了价值近5.5亿美元的库存，&#34;主要与Orforglipron相关&#34;。这表明礼来正在建立产品库存，避免诺和诺德和自身注射型GLP-1药物曾面临的供应短缺问题。</p><p style=\"text-align: justify;\">Leerink Partners分析师David Risinger表示：礼来将成为唯一一家拥有易于生产的口服GLP-1药物的公司，领先新竞争对手近三年。这一优势将使礼来能够在更长时间内保持更高定价能力。</p><h2 id=\"id_999662048\">登顶减肥药之王？</h2><p style=\"text-align: justify;\">此前提及，在礼来公布这一振奋人心的消息的同一周，其竞争对手<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>宣布停止开发其口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。</p><p style=\"text-align: justify;\">与此同时，诺和诺德自去年6月以来持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳，导致其本月痛失欧股市值老大的位置。</p><p style=\"text-align: justify;\">GLP-1减肥药市场预计将从目前的280亿美元迅速增长至2030年的约950亿美元。根据<a href=\"https://laohu8.com/S/GS\">高盛</a>分析师的预测，Orforglipron的风险调整后峰值销售额(包括肥胖和糖尿病)将在2035年达到235亿美元，远高于市场共识的168亿美元。</p><p style=\"text-align: justify;\">为避免类似注射型GLP-1药物的供应短缺问题，礼来已经开始积极备货Orforglipron，最近披露的价值近5.5亿美元的库存&#34;主要与Orforglipron相关&#34;。有报道称，公司计划在5年内实现Orforglipron在美国的全部供应本地化生产。</p><p style=\"text-align: justify;\">根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。该公司计划今年晚些时候寻求减重适应症的监管批准，明年初则将申请糖尿病适应症。如果一切顺利，分析师预计该药物最早可能在2026年上半年获得FDA批准上市。</p></body></html>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥神药”进入口服时代，礼来登顶“减肥药王”？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥神药”进入口服时代，礼来登顶“减肥药王”？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-18 09:36 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3745456><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3745456\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"LLY":"礼来","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4581":"高盛持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4516":"特朗普概念"},"source_url":"https://wallstreetcn.com/articles/3745456","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170316139","content_text":"华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下自2023年8月以来的最大单日涨幅。与此同时，长期占据GLP-1市场主导地位的诺和诺德股价则大幅收跌近8%。根据礼来公布发布的新闻稿，其口服GLP-1药物orforglipron在3期临床试验中“展示了统计学上显著的疗效结果，且安全性与注射型GLP-1药物一致”。数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。\"这些数据代表了一款一上市就能成为重磅产品的最佳情况，\"Jefferies分析师Akash Tewari表示。瑞穗证券医疗保健专家Jared Holz表示，礼来将在相当长一段时间内保持该类别中的卓越地位，因为基于这些数据，其领先于制药和生物技术领域竞争对手的优势正在扩大。华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司董事长兼CEO David Ricks在一份声明中写道：\"作为一种方便的每日一次口服药丸，Orforglipron可能提供了一个新选择，如获批准，可迅速大规模生产和推出，供全球人使用。\"口服药物：便利性与制造优势的双重胜利Orforglipron是一种更便捷的口服替代GLP-1注射剂的治疗方案，这给礼来带来了超越诺和诺德等竞争对手的潜在优势。礼来的Orforglipron不仅在疗效上具有竞争力，其口服给药方式还提供了显著的便利性优势。据报道，虽然目前市场上已有GLP-1类药物如Wegovy获得巨大成功，但这些药物必须以每周注射的方式给药，这限制了它们的使用范围。如果Orforglipron能以简单的口服形式提供类似的效果，它有潜力接触到更多患者并成为重大的市场颠覆者。除了便利性外，礼来还在积极准备大规模生产Orforglipron。该公司最近披露了价值近5.5亿美元的库存，\"主要与Orforglipron相关\"。这表明礼来正在建立产品库存，避免诺和诺德和自身注射型GLP-1药物曾面临的供应短缺问题。Leerink Partners分析师David Risinger表示：礼来将成为唯一一家拥有易于生产的口服GLP-1药物的公司，领先新竞争对手近三年。这一优势将使礼来能够在更长时间内保持更高定价能力。登顶减肥药之王？此前提及，在礼来公布这一振奋人心的消息的同一周，其竞争对手辉瑞宣布停止开发其口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。与此同时，诺和诺德自去年6月以来持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳，导致其本月痛失欧股市值老大的位置。GLP-1减肥药市场预计将从目前的280亿美元迅速增长至2030年的约950亿美元。根据高盛分析师的预测，Orforglipron的风险调整后峰值销售额(包括肥胖和糖尿病)将在2035年达到235亿美元，远高于市场共识的168亿美元。为避免类似注射型GLP-1药物的供应短缺问题，礼来已经开始积极备货Orforglipron，最近披露的价值近5.5亿美元的库存\"主要与Orforglipron相关\"。有报道称，公司计划在5年内实现Orforglipron在美国的全部供应本地化生产。根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。该公司计划今年晚些时候寻求减重适应症的监管批准，明年初则将申请糖尿病适应症。如果一切顺利，分析师预计该药物最早可能在2026年上半年获得FDA批准上市。","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869726883,"gmtCreate":1632323199642,"gmtModify":1632330364141,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","text":"$Cassava Sciences Inc(SAVA)$Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":23,"repostSize":0,"link":"https://laohu8.com/post/869726883","isVote":1,"tweetType":1,"viewCount":6647,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559212851859453","authorId":"3559212851859453","name":"赵山河000","avatar":"https://static.tigerbbs.com/831a3e6550cf42c5e68dfa8f771d60ce","crmLevel":2,"crmLevelSwitch":0,"idStr":"3559212851859453","authorIdStr":"3559212851859453"},"content":"每次都是“sell on news” 今天又过山车了😊","text":"每次都是“sell on news” 今天又过山车了😊","html":"每次都是“sell on news” 今天又过山车了😊"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":884244779,"gmtCreate":1631900640391,"gmtModify":1631900640391,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","text":"$Cassava Sciences Inc(SAVA)$9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884244779","isVote":1,"tweetType":1,"viewCount":6613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883343723,"gmtCreate":1631207793762,"gmtModify":1631207793762,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","text":"$Cassava Sciences Inc(SAVA)$如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/883343723","isVote":1,"tweetType":1,"viewCount":4764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815519041,"gmtCreate":1630688977183,"gmtModify":1630688977183,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天没有什么利空消息啊，为什么跌这么狠？","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天没有什么利空消息啊，为什么跌这么狠？","text":"$Cassava Sciences Inc(SAVA)$Sava今天没有什么利空消息啊，为什么跌这么狠？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815519041","isVote":1,"tweetType":1,"viewCount":6519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812168249,"gmtCreate":1630565108881,"gmtModify":1630565108881,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","text":"$Cassava Sciences Inc(SAVA)$Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/812168249","isVote":1,"tweetType":1,"viewCount":2676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":811527070,"gmtCreate":1630333076690,"gmtModify":1704958654615,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava基本筑底横盘，等待消息面来决定向上或向下？","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava基本筑底横盘，等待消息面来决定向上或向下？","text":"$Cassava Sciences Inc(SAVA)$Sava基本筑底横盘，等待消息面来决定向上或向下？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/811527070","isVote":1,"tweetType":1,"viewCount":5910,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":813770849,"gmtCreate":1630258662581,"gmtModify":1704957503924,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","text":"$Cassava Sciences Inc(SAVA)$截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/813770849","isVote":1,"tweetType":1,"viewCount":7543,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578972987976233","authorId":"3578972987976233","name":"泥巴124","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3578972987976233","authorIdStr":"3578972987976233"},"content":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！","text":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！","html":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":869726883,"gmtCreate":1632323199642,"gmtModify":1632330364141,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","text":"$Cassava Sciences Inc(SAVA)$Sava今天公布了12-month数据，增强了我的信心。尽管今天又大跌，但一点都不担心。估计很快就会公布phase-3启动的消息，预计两周内就会公布。","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":23,"repostSize":0,"link":"https://laohu8.com/post/869726883","isVote":1,"tweetType":1,"viewCount":6647,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559212851859453","authorId":"3559212851859453","name":"赵山河000","avatar":"https://static.tigerbbs.com/831a3e6550cf42c5e68dfa8f771d60ce","crmLevel":2,"crmLevelSwitch":0,"idStr":"3559212851859453","authorIdStr":"3559212851859453"},"content":"每次都是“sell on news” 今天又过山车了😊","text":"每次都是“sell on news” 今天又过山车了😊","html":"每次都是“sell on news” 今天又过山车了😊"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":811527070,"gmtCreate":1630333076690,"gmtModify":1704958654615,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava基本筑底横盘，等待消息面来决定向上或向下？","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava基本筑底横盘，等待消息面来决定向上或向下？","text":"$Cassava Sciences Inc(SAVA)$Sava基本筑底横盘，等待消息面来决定向上或向下？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/811527070","isVote":1,"tweetType":1,"viewCount":5910,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":813770849,"gmtCreate":1630258662581,"gmtModify":1704957503924,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","text":"$Cassava Sciences Inc(SAVA)$截止8/27/21，SAVA股票的做空比率已经达到惊人的40.48%？接下来的一周是关键。希望SAVA能给出有力的证据回击造假的指控。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/813770849","isVote":1,"tweetType":1,"viewCount":7543,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578972987976233","authorId":"3578972987976233","name":"泥巴124","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3578972987976233","authorIdStr":"3578972987976233"},"content":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！","text":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！","html":"我看空头信号都归0了，不过反弹回来估计要时间了，毕竟这次做空是有备而来，带节奏点，掐时机的，步步为营。现在回应也只是防守，大反弹应该也得要找个好的时间和时机规划，看公司CEO能力了，大部分高成长企业都是要过这种生死关，很正常！"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":884244779,"gmtCreate":1631900640391,"gmtModify":1631900640391,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","text":"$Cassava Sciences Inc(SAVA)$9月21日 阿尔茨海默症日期待phase 3启动等利好消息！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884244779","isVote":1,"tweetType":1,"viewCount":6613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815519041,"gmtCreate":1630688977183,"gmtModify":1630688977183,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天没有什么利空消息啊，为什么跌这么狠？","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava今天没有什么利空消息啊，为什么跌这么狠？","text":"$Cassava Sciences Inc(SAVA)$Sava今天没有什么利空消息啊，为什么跌这么狠？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815519041","isVote":1,"tweetType":1,"viewCount":6519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883343723,"gmtCreate":1631207793762,"gmtModify":1631207793762,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","text":"$Cassava Sciences Inc(SAVA)$如果今天能站上50关键支撑位，就有止跌企稳迹象。下周若有利好消息就能向上突破。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/883343723","isVote":1,"tweetType":1,"viewCount":4764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812168249,"gmtCreate":1630565108881,"gmtModify":1630565108881,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","text":"$Cassava Sciences Inc(SAVA)$Sava的CEO Remi加仓了象征性的加仓了2801股，至少是一个积极的信号，表明内部对数据真实性还是很有信心的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/812168249","isVote":1,"tweetType":1,"viewCount":2676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":425760610320536,"gmtCreate":1744955620558,"gmtModify":1744955622512,"author":{"id":"3561484276442419","authorId":"3561484276442419","name":"winbull","avatar":"https://static.tigerbbs.com/2721b4659074c648208dd967729ddb25","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3561484276442419","authorIdStr":"3561484276442419"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425760610320536","repostId":"1170316139","repostType":4,"repost":{"id":"1170316139","kind":"news","pubTimestamp":1744940179,"share":"https://www.laohu8.com/m/news/1170316139?lang=&edition=full","pubTime":"2025-04-18 09:36","market":"us","language":"zh","title":"“减肥神药”进入口服时代，礼来登顶“减肥药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1170316139","media":"华尔街见闻","summary":"数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。登顶减肥药之王？报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。","content":"<html><head></head><body><blockquote><p>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而<a href=\"https://laohu8.com/S/LLY\">礼来</a>已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。</p></blockquote><p style=\"text-align: justify;\">礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。</p><p style=\"text-align: justify;\">市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下自2023年8月以来的最大单日涨幅。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe90ecd263678e278cba37dd80d837f5\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: justify;\">与此同时，长期占据GLP-1市场主导地位的<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>股价则大幅收跌近8%。</p><p style=\"text-align: justify;\">根据礼来公布发布的新闻稿，其口服GLP-1药物orforglipron在3期临床试验中“展示了统计学上显著的疗效结果，且安全性与注射型GLP-1药物一致”。</p><p style=\"text-align: justify;\">数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3719b80ed8bbed049f77705d8b2b4a75\" title=\"\" tg-width=\"873\" tg-height=\"530\"/></p><p style=\"text-align: justify;\">相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。</p><p style=\"text-align: justify;\">&#34;这些数据代表了一款一上市就能成为重磅产品的最佳情况，&#34;Jefferies分析师Akash Tewari表示。</p><p style=\"text-align: justify;\">瑞穗证券医疗保健专家Jared Holz表示，礼来将在相当长一段时间内保持该类别中的卓越地位，因为基于这些数据，其领先于制药和生物技术领域竞争对手的优势正在扩大。</p><p style=\"text-align: justify;\"><strong>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。</strong></p><p style=\"text-align: justify;\">礼来公司董事长兼CEO David Ricks在一份声明中写道：</p><blockquote><p style=\"text-align: justify;\">&#34;作为一种方便的每日一次口服药丸，Orforglipron可能提供了一个新选择，如获批准，可迅速大规模生产和推出，供全球人使用。&#34;</p></blockquote><h2 id=\"id_1383858797\">口服药物：便利性与制造优势的双重胜利</h2><p style=\"text-align: justify;\">Orforglipron是一种更便捷的口服替代GLP-1注射剂的治疗方案，这给礼来带来了超越诺和诺德等竞争对手的潜在优势。</p><p style=\"text-align: justify;\">礼来的Orforglipron不仅在疗效上具有竞争力，其口服给药方式还提供了显著的便利性优势。</p><p style=\"text-align: justify;\">据报道，虽然目前市场上已有GLP-1类药物如Wegovy获得巨大成功，但这些药物必须以每周注射的方式给药，这限制了它们的使用范围。</p><blockquote><p style=\"text-align: justify;\">如果Orforglipron能以简单的口服形式提供类似的效果，它有潜力接触到更多患者并成为重大的市场颠覆者。</p></blockquote><p style=\"text-align: justify;\">除了便利性外，礼来还在积极准备大规模生产Orforglipron。该公司最近披露了价值近5.5亿美元的库存，&#34;主要与Orforglipron相关&#34;。这表明礼来正在建立产品库存，避免诺和诺德和自身注射型GLP-1药物曾面临的供应短缺问题。</p><p style=\"text-align: justify;\">Leerink Partners分析师David Risinger表示：礼来将成为唯一一家拥有易于生产的口服GLP-1药物的公司，领先新竞争对手近三年。这一优势将使礼来能够在更长时间内保持更高定价能力。</p><h2 id=\"id_999662048\">登顶减肥药之王？</h2><p style=\"text-align: justify;\">此前提及，在礼来公布这一振奋人心的消息的同一周，其竞争对手<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>宣布停止开发其口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。</p><p style=\"text-align: justify;\">与此同时，诺和诺德自去年6月以来持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳，导致其本月痛失欧股市值老大的位置。</p><p style=\"text-align: justify;\">GLP-1减肥药市场预计将从目前的280亿美元迅速增长至2030年的约950亿美元。根据<a href=\"https://laohu8.com/S/GS\">高盛</a>分析师的预测，Orforglipron的风险调整后峰值销售额(包括肥胖和糖尿病)将在2035年达到235亿美元，远高于市场共识的168亿美元。</p><p style=\"text-align: justify;\">为避免类似注射型GLP-1药物的供应短缺问题，礼来已经开始积极备货Orforglipron，最近披露的价值近5.5亿美元的库存&#34;主要与Orforglipron相关&#34;。有报道称，公司计划在5年内实现Orforglipron在美国的全部供应本地化生产。</p><p style=\"text-align: justify;\">根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。该公司计划今年晚些时候寻求减重适应症的监管批准，明年初则将申请糖尿病适应症。如果一切顺利，分析师预计该药物最早可能在2026年上半年获得FDA批准上市。</p></body></html>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥神药”进入口服时代，礼来登顶“减肥药王”？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥神药”进入口服时代，礼来登顶“减肥药王”？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-18 09:36 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3745456><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3745456\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"LLY":"礼来","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4581":"高盛持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4516":"特朗普概念"},"source_url":"https://wallstreetcn.com/articles/3745456","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170316139","content_text":"华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色，可以媲美甚至超越注射型GLP-1药物。市场对礼来的突破性进展反应强烈。4月17日，礼来股价收涨超14%，盘中暴涨16%，创下自2023年8月以来的最大单日涨幅。与此同时，长期占据GLP-1市场主导地位的诺和诺德股价则大幅收跌近8%。根据礼来公布发布的新闻稿，其口服GLP-1药物orforglipron在3期临床试验中“展示了统计学上显著的疗效结果，且安全性与注射型GLP-1药物一致”。数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。\"这些数据代表了一款一上市就能成为重磅产品的最佳情况，\"Jefferies分析师Akash Tewari表示。瑞穗证券医疗保健专家Jared Holz表示，礼来将在相当长一段时间内保持该类别中的卓越地位，因为基于这些数据，其领先于制药和生物技术领域竞争对手的优势正在扩大。华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家，至少目前看来，礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司董事长兼CEO David Ricks在一份声明中写道：\"作为一种方便的每日一次口服药丸，Orforglipron可能提供了一个新选择，如获批准，可迅速大规模生产和推出，供全球人使用。\"口服药物：便利性与制造优势的双重胜利Orforglipron是一种更便捷的口服替代GLP-1注射剂的治疗方案，这给礼来带来了超越诺和诺德等竞争对手的潜在优势。礼来的Orforglipron不仅在疗效上具有竞争力，其口服给药方式还提供了显著的便利性优势。据报道，虽然目前市场上已有GLP-1类药物如Wegovy获得巨大成功，但这些药物必须以每周注射的方式给药，这限制了它们的使用范围。如果Orforglipron能以简单的口服形式提供类似的效果，它有潜力接触到更多患者并成为重大的市场颠覆者。除了便利性外，礼来还在积极准备大规模生产Orforglipron。该公司最近披露了价值近5.5亿美元的库存，\"主要与Orforglipron相关\"。这表明礼来正在建立产品库存，避免诺和诺德和自身注射型GLP-1药物曾面临的供应短缺问题。Leerink Partners分析师David Risinger表示：礼来将成为唯一一家拥有易于生产的口服GLP-1药物的公司，领先新竞争对手近三年。这一优势将使礼来能够在更长时间内保持更高定价能力。登顶减肥药之王？此前提及，在礼来公布这一振奋人心的消息的同一周，其竞争对手辉瑞宣布停止开发其口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。与此同时，诺和诺德自去年6月以来持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳，导致其本月痛失欧股市值老大的位置。GLP-1减肥药市场预计将从目前的280亿美元迅速增长至2030年的约950亿美元。根据高盛分析师的预测，Orforglipron的风险调整后峰值销售额(包括肥胖和糖尿病)将在2035年达到235亿美元，远高于市场共识的168亿美元。为避免类似注射型GLP-1药物的供应短缺问题，礼来已经开始积极备货Orforglipron，最近披露的价值近5.5亿美元的库存\"主要与Orforglipron相关\"。有报道称，公司计划在5年内实现Orforglipron在美国的全部供应本地化生产。根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。该公司计划今年晚些时候寻求减重适应症的监管批准，明年初则将申请糖尿病适应症。如果一切顺利，分析师预计该药物最早可能在2026年上半年获得FDA批准上市。","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}